Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (GSK, ee4973)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is a pandemic influenza vaccine developed by GSK for the prevention of disease caused by the H5N1 subtype of avian influenza. The vaccine is composed of monovalent, inactivated, split A/H5N1 influenza virus antigen combined with GSK's proprietary AS03 adjuvant system, which is an oil-in-water emulsion containing alpha-tocopherol and squalene. It works by stimulating the immune system to produce antibodies against the viral hemagglutinin protein, providing protection against highly pathogenic avian influenza. It received U.S. FDA approval in 2013 for use in individuals 6 months and older at increased risk of exposure, and is also known by the brand names Pumarix in Europe and Arepanrix H5N1 in Canada.
- Brand names
- PumarixArepanrix H5N1
- Other names
- Influenza A (H5N1) Virus Monovalent Vaccine, AdjuvantedH5N1 vaccineH-5N1 vaccineH 5N1 vaccineA/turkey H5N1 vaccineA/Indonesia H5N1 vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (GSK, ee4973).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (GSK, ee4973).